IDYA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
IDEAYA Biosciences (IDYA) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong positive catalysts, including upcoming clinical trial data, robust analyst ratings with significant upside potential, and solid financial growth in revenue. While technical indicators are neutral, the SwingMax signal and options sentiment suggest a favorable entry point.
The MACD is below 0 and negatively contracting, indicating a neutral to slightly bearish momentum. RSI is at 59.129, which is neutral, and moving averages are converging. Key support and resistance levels are at S1: 30.022 and R1: 33.454, with the stock closing near resistance. Overall, the technical indicators are neutral.
Upcoming Phase 2/3 OptimUM-02 trial data for metastatic uveal melanoma, expected at the end of March, with analysts projecting an 85% probability of success.
Strong analyst ratings and price target increases, with targets ranging from $45 to $
Revenue growth of 55% YoY in Q4 2025 and reduced R&D expenses.
Collaboration revenue increased significantly, and the company has a strong cash position of $1.05 billion.
Net income and EPS have declined YoY, reflecting ongoing losses.
High implied volatility (102.
indicates elevated risk.
No significant hedge fund or insider trading activity to confirm strong institutional confidence.
In Q4 2025, revenue increased by 55.37% YoY to $10.88 million, driven by collaboration revenue. However, net income dropped by 36.10% YoY to -$83.27 million, and EPS fell by 36.91% to -$0.94. R&D expenses decreased by 38% to $86.6 million, indicating cost management efforts. The company has a strong cash position of $1.05 billion.
Analysts are highly bullish on IDYA, with multiple firms raising price targets recently. Citi raised its target to $65, Wedbush to $52, RBC Capital to $45, UBS to $50, and Truist to $60. Analysts cite strong Phase II data, favorable risk-reward profiles, and key upcoming catalysts as reasons for their optimism.
